Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry
Mena-Vázquez, Natalia; Fernández-Nebro, Antonio; Pego-Reigosa, José María; Galindo, María; Melissa-Anzola, Ana; Uriarte-Isacelay, Esther; Olivé-Marqués, Alejandro; Aurrecoechea, Elena; Freire Gonzalez, Mercedes; Tomero, Eva; García-Villanueva, María Jesús; Stoye, Claudia; Salas-Heredia, Esteban; Bernal-Vidal, Jose Antonio; Salgado Pérez, Eva; Blanco, Ricardo; Javier Novoa, Francisco; Ibáñez-Barcelo, Mónica; Torrente-Segarra, Vicente; Narvaez, Javier; Calvet, Joan; Moriano Morales, Clara; Ramon Vazquez-Rodriguez, Tomas; Garcia de la Peña, Paloma; Bohórquez, Cristina; Andreu-Sánchez, José Luis; Cobo-Ibañez, Tatiana; Bonilla, Gema; Lozano-Rivas, Nuria; Montilla, Carlos; Toyos, Francisco Javier; De la Fuente, Jose Luis Marenco; Expósito, Lorena; Ruiz-Lucea, María Esther; Vals, Elia; Manero-Ruiz, Javier; Bernal-Vidal, Jose A; Rua-Figueroa, Iñigo
Files view or download
Files view or download
Type of content
DeCSautoinmunidad | adulto joven | mediana edad | humanos | estudios transversales | antirreumáticos | adulto | sistema de registros | hidroxicloroquina | enfermedades autoinmunes
MeSHAdult | Middle Aged | Humans | Registries | Antirheumatic Agents | Cross-Sectional Studies | Young Adult | Autoimmune Diseases | Hydroxychloroquine | Autoimmunity
OBJECTIVES: This article estimates the frequency of polyautoimmunity and associated factors in a large retrospective cohort of patients with SLE. METHODS: RELESSER (Spanish Society of Rheumatology Lupus Registry) is a nationwide multicentre, hospital-based registry of SLE patients. This is a cross-sectional study. The main variable was polyautoimmunity, which was defined as the co-occurrence of SLE and another autoimmune disease, such as autoimmune thyroiditis, RA, scleroderma, inflammatory myopathy and MCTD. We also recorded the presence of multiple autoimmune syndrome, secondary SS, secondary APS and a family history of autoimmune disease. Multiple logistic regression analysis was performed to investigate possible risk factors for polyautoimmunity. RESULTS: Of the 3679 patients who fulfilled the criteria for SLE, 502 (13.6%) had polyautoimmunity. The most frequent types were autoimmune thyroiditis (7.9%), other systemic autoimmune diseases (6.2%), secondary SS (14.1%) and secondary APS (13.7%). Multiple autoimmune syndrome accounted for 10.2% of all cases of polyautoimmunity. A family history was recorded in 11.8%. According to the multivariate analysis, the factors associated with polyautoimmunity were female sex [odds ratio (95% CI), 1.72 (1.07, 2.72)], RP [1.63 (1.29, 2.05)], interstitial lung disease [3.35 (1.84, 6.01)], Jaccoud arthropathy [1.92 (1.40, 2.63)], anti-Ro/SSA and/or anti-La/SSB autoantibodies [2.03 (1.55, 2.67)], anti-RNP antibodies [1.48 (1.16, 1.90)], MTX [1.67 (1.26, 2.18)] and antimalarial drugs [0.50 (0.38, 0.67)]. CONCLUSION: Patients with SLE frequently present polyautoimmunity. We observed clinical and analytical characteristics associated with polyautoimmunity. Our finding that antimalarial drugs protected against polyautoimmunity should be verified in future studies.